

JORNADA RIVs — PRESENTACIÓN PRECISEU



PRECISEU

1 JUL 25



Co-funded by
the European Union

This project has received funding from the European Union's Horizon Europe research and innovation program under Grant Agreement No 101161301

Transformative approach that uses an individual's genetic profile to guide decisions made in regard to the prevention, diagnosis, and treatment of disease.

THE REGIONAL INNOVATION VALLEY ON PERSONALISED MEDICINE




- **Flagship project** to address **main challenges** of **Personalized Medicine** towards 5P Healthcare (*preventive, personalized, predictive, patient-centered/ participatory/ population/ planetary*), in a **shorter time**.
- A **unique opportunity for Europe** to lead the path and **engage Ukraine** in networks of innovative hubs for a shared future
- **Draghi's** recommends funding and developing a limited number of **world-class innovation hubs in life sciences**, particularly in ATMPs.

**25 PARTNERS, 23 M€, 5 YEARS,
11 COUNTRIES (10 MS), 12 REGIONS**




THE PRECISEU CONCEPT



- MINIMUM 4 CONSORTIA FUNDED
- “IA-LIKE” PROJECTS
- TOPICS RELATED TO PERSONALISED MEDICINE: HEALTH DATA AND ATMPs
- TRL 6-8
- PUBLIC AND PRIVATE BENEFICIARIES

PRECISEU WPs

WP1 –Project Management and Coordination BIOCAT	WP2 – Communication and Dissemination NE RDA	WP3 – Interregional Collaboration and Partnership Bridging IA LIT
<p>Coordination, internal communication, conflict resolution, monitoring.</p>	<p>Engagement of stakeholders, setting up and launching PRECISEU Platform.</p>	<p>Complementarity to large initiatives and policies – EP Permed</p>
WP4 – Use of Health data ART-ER	WP5 – Multistakeholder ATMP infrastructure BIOPRO	WP6 – Market and Patient access SSP
<p>Map and assess readiness and maturity towards EHDS. Address hosting, curation and processing; and interoperability issues.</p>	<p>Multi-stakeholder infrastructure, to adapt or customize to ATMP developer’s needs.</p>	<p>Mapping market gaps and rules regarding health data and ATMPs. Collaboration with industry and business models for PM.</p>
WP7 – Training and cultural change HLSCB	WP8 – Adoption in the Health Care System SALUT	WP9 – Innovation support program BIOCAT
<p>Capacity building, mentoring and training. Foster the culture of PM, and awards to good practices.</p>	<p>Sustainable and affordable PM into healthcare, procurement and reimbursement.</p>	<p>Launching and funding 20-30 beneficiaries on Health Data and ATMPs. Sustainable and affordable PM in healthcare</p>



PRECISEU REGIONAL INNOVATION VALLEY 12 MONTHS ACHIEVEMENTS



- 500+ stakeholders
 - All Ecosystem engagement
- Complex Governance
- Advisory Board: 11 global experts
 - 2 GAMs (100 participants)
 - 10 monthly meetings
 - Collaboration EC and EISMEA

- Case Studies (EU Presidencies): HUNGARY AND POLAND. Ongoing: DENMARK
- With EP Permed: PM in Health Systems
- PRECISEU Recognition Awards (September 18th 2025, Vilnius)

- PRECISEU School on PM (July, Iasi – Romania; October, Gothenburg, Sweden) (of a total of 8)
- *Design Thinking* for Policy makers (November 25, Barcelona, of a total of 4)

- 25+ events
- 2 in EU Presidencies
- 1500+ attendees
- Web, Newsletters internal / external, LinkedIn
- Positioning in EC initiatives: Startups / Scaleups
- Global Hackathon
- Regional Innovation Valley Label on Personalised Medicine



- EHDS maturity grid for regions and countries in PRECISEU
- FactSheet as a summary, to be used in policymaking
- Expert webinars
- Reports and guidelines

- International alliances EP Permed, TEHDAS2, Elixir, COBioE, EIT Health, ATMP Sweden, RegMed Alliance, Deloitte Next Gen Group...
- 5 RIV Board

- Launching of EOIs
- Preparation of Support Program
- Preparation of Call to IAs (min 4 JIPs, max 3 M/project)

- PM barriers and enablers
- ATMP Market access per regions
- Pan EU mapping



Call


- 1 OPEN CALL (a preliminary EoI)

Budget

- 11.570.000 € (50% Horizon Europe, 50% partners/regional authorities - different types of funding agencies)

Topic (SRIA's ToA)

- Deep tech innovation, including Advanced therapy medicinal products (ATMPs) and Health Data
- Projects must help bring the technology or solution to a higher TRL level, starting from TRL6 to TRL8.
- Projects must address SRIA's ToA
- Projects must address challenges identified in WP3-8 of PRECISEU
- Joint Interregional projects with public and private partners



DATES

Action	Dates
Expression of Interest submission	20 May 2025 - 31 July 2025
Funnelling process	1 July 2025 - 31 October 2025
Open Call for proposals	1 November 2025 - 31 December 2025
Proposals Evaluation	1 January 2026 - 30 January 2026
Announcement of Awards	1 February 2026
Grant Agreement Signature	1 February 2026 – 28 February 2026
Implementation of the Joint Interregional Projects	1 March 2026 – 28 February 2029
JIP and FSTP Assessment	1 March 2029 – 31 April 2029
Final Payments	1 May 2029 – 1 June 2029

CONDITIONS

Concept	Conditions
Budget	The maximum amount committed for this call is €11,570,000.00 co-funded (50%) by the European Union through the Horizon Europe programme, under Grant Agreement No 101161301.
Funding rate	<p>For entities established in any of the PRECISEU regions in which the authorities or investment agencies have committed funding for the Financial Support to Third Parties (FSTP):</p> <ul style="list-style-type: none"> ○ 70% for profit-making legal entities and 100% for non-profit legal entities. ○ Up to 600.000 euros per entity (if located in PRECISEU funding regions). <p>For any other entities located either in PRECISEU regions that are not co-funding the FSTP calls or any other regions: no cofunding is foreseen, and special agreements must be made with the corresponding regional authorities.</p>
Opening and closing date	Call for proposals will remain open between 1 November 2025 and 31 December 2025.
Target beneficiaries	Target organisations include SMEs, startups/spinoffs, public and private research bodies, hospitals, NGOs (including patient organisations), and large companies with a validated EC number from i) PRECISEU regions providing funding, ii) PRECISEU regions not providing funding or iii) from regions in EU MS and HE AC (with different conditions applying according to the region of origin).

Maximum number of applications per organisation	One
Type of activities that qualify for financial support	<ul style="list-style-type: none"> ○ Scale-up production. ○ Optimisation, validation and standardisation of the analytical methods, protocols and methodologies ○ Study of mechanisms of action and pathways involved ○ Development of suitable and (environmentally) relevant reference materials that can be used to improve robustness and comparability across laboratories ○ Development of improved in-vivo, in-silico and in-vitro models ○ Generation of evidence ○ End-user collaborative projects (engagement of patients, healthcare practitioners, clinicians, and relevant healthcare authorities to support and enhance clinical development). ○ Use of health data repositories to facilitate/support the clinical validation of a technology. ○ Activities related to adoption and distribution of new or soon-to-be-approved products. <p>For a more complete list, see section 3 of this document.</p>
Minimum Technology Readiness Level (TRL) of the project/solution	Projects must help bring the technology or solution to a higher TRL level, from TRL6 to TRL8.
Projects implementation period	Projects can be implemented from 1 March 2026 to 28 February 2029

ELEGIBILITY

Action	Eligibility	Conditions
Expression of Interest	PRECISEU Regions (see boxes 1 and 2, page 17)	Entities from PRECISEU regions not contributing to FSTP can submit EoIs but the feasibility will be assessed case per case
Funnelling process	PRECISEU Regions (see boxes 1 and 2, page 17)	Entities from PRECISEU regions not contributing to FSTP can enter the funnelling but not lead a consortium.
	Non-PRECISEU regions from EU MS and HE AC	Entities may join a consortium (as beneficiaries, not coordinators), if requested by the consortium.
Open Call for proposals	PRECISEU Regions contributing to FSTP (see Box 1, page 17)	Eligible for funding (see annex 3 for details)
	PRECISEU Regions not providing FSTP funding (see Box 2, page 17)	Can participate but are not eligible for funding. Only 1 entity not receiving funding can join a consortium.
	Non-PRECISEU regions from EU MS and HE AC	Can join a consortium (not as coordinators). Only 1 entity not receiving funding can join consortium.


Funding agency	Region	Economic resources	Target organisations	Funding contribution and rate	Pre-financing	Form
EISMEA	HORIZON EUROPE	€5,785,000 (as 50% of all the funding provided by the agencies below)	Public and Private	100% for public entities, 70% for private entities. Up to €300.000 per entity	Possible	Lump Sum
BIOCAT	Catalonia, Spain	€200,000 (50% co-funded)	Public and Private	€300,000 per entity (100% for public entities and 70% for private entities).	Possible	Lump sum
SALUT	Catalonia, Spain	€4,000,000 (50% co-funded)	Public and Private	€300,000 per entity (100% for public entities and 70% for private entities).	Possible	Lump sum
ACCIO	Catalonia, Spain	€600,000 (50% co-funded)	Public and Private	€300,000 per entity (100% for public entities and 70% for private entities).	Possible	Lump sum
BIOPRO	Baden-Württemberg, Germany	€1,600,000 (50% co-funded)	Public and Private	€300,000 per entity (100% for public entities and 70% for private entities).	Possible	
NERDA	Romania	€1,000,000 (50% co-funded)	SMEs (no regional partnership demanded) established as an entity with	€300,000 per entity with a 10% contribution from the beneficiary €300,000 max grant with 30% contribution from the beneficiary	Possible	Correlated with regional program conditions
DIZNE	Romania	€70,000 (50% co-funded)			Possible	

Funding agency	Region	Economic resources	Target organisations	Funding contribution and rate	Pre-financing	Form
			legal personality according to Romanian Law for SMEs with registered office in the North-East Romania Region			
SIA	Bulgaria	€1,500,000 (50% co-funded)	Public and Private	€300,000 per entity (100% for public entities and 70% for private entities).	Possible	
RER	Emilia-Romagna, Italy	€1,800,000 (50% co-funded)	Universities, research centers, enterprises (not only SMEs)	Co-fund for universities and research centers from 70% to 90% (ERDF funds). Enterprises (covered by HORIZON funds) funded at 90%	Not possible (not foreseen in ER calls)	2 contemporary calls: ERDF (following ERDF regulations) addressed to universities and research centers. HORIZON funding addressed to enterprises, as a lump sum.
IA Lithuania	Lithuania	€200,000 (50% co-funded)		€300,000 per entity (70% for private entities).	Possible	Lump Sum



Funding agency	Region	Economic resources	Target organisations	Funding contribution and rate		Pre-financing	Form
REGION OF CRETE	Crete, Greece	€600,000 (50% co-funded)	is referred to the appendix	<u>INDUSTRIAL/APPLIED RESEARCH</u> <ul style="list-style-type: none"> • Large Enterprises: <u>65%</u> • Medium Enterprises: <u>70%</u> • Small Enterprises: <u>70%</u> • Public Research, <u>other public units and other non-profit entities:</u> <u>100%</u> 	<u>EXPERIMENTAL RESEARCH</u> <ul style="list-style-type: none"> • <u>Large Enterprises:</u> <u>40%</u> • <u>Medium Enterprises:</u> <u>50%</u> • <u>Small Enterprises:</u> <u>60%</u> • <u>Public Research, other public units and other non-profit entities:</u> <u>100%</u> 	is referred to the appendix	Lump Sum

THE FUTURE





PRECISEU



Co-funded by
the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme under Grant Agreement No 101161301